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SuMMAry – Bone morphogenetic protein-7 (BMP-7) is expressed in all parts of the normal 
kidney parenchyma, being highest in the epithelium of proximal tubules. it protects kidney against 
acute and chronic injury, inflammation and fibrosis. diabetic nephropathy is the leading cause of 
chronic kidney disease, and is characterized by decreased expression of BMP-7. The aim of our study 
was to analyze whether the expression of BMP-7 is significantly changed in advanced stages of 
human diabetic nephropathy. immunohistochemical analysis of the expression of BMP-7 was per-
formed on archival material of 30 patients that underwent renal biopsy and had confirmed diagnosis 
of diabetic nephropathy. results showed that BMP-7 was differently expressed in the cytoplasm of 
epithelial cells of proximal tubules and podocytes among all stages of diabetic nephropathy. At early 
stages of diabetic nephropathy, BMP-7 was strongly positive in proximal tubules and podocytes, 
while low expression was recorded in the majority of samples at advanced stages. in conclusion, 
increased expression of BMP-7 at initial stages of diabetic nephropathy with subsequent decrease 
at advanced stage highlights the role of BMP-7 in the protection of kidney structure and function. 
Further investigations should be focused on disturbances of BMP-7 receptors and signaling pat-
hways in patients with diabetic nephropathy. 
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Introduction
Bone morphogenetic proteins (BMPs) are mem-
bers of the transforming growth factor beta superfam-
ily. They are also known as osteogenic proteins (OPs), 
and were originally identified by their ability to induce 
the formation of endochondral bone at extraskeletal 
sites1,2. BMP-7 is synthesized predominantly in the 
kidney at gestational age of 5-14 weeks3,4, and has 
been recognized as a key signaling molecule during 
kidney development5. it is mostly expressed in the 
epithelial cells of the glomeruli and distal tubules in 
the kidney6. BMP-7 has the ability to protect kidney 
against acute renal failure in postnatal life5. 
The absence of BMP-7 gene expression in mice 
causes uremia and death within 24 h after birth, and 
dysplastic kidneys and hydroureter are found on autop-
sy7. experimental animal models of acute and chronic 
renal injury confirmed the important role of BMP-7 in 
the prevention of inflammation and fibrosis8.
Several studies confirmed that expression of 
BMP-7 and the number of podocytes are decreased in 
diabetic nephropathy9. in diabetic nephropathy, tubu-
lar cells produce a large amount of extracellular matrix 
proteins, which leads to interstitial fibrosis. BMP-7 
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can reduce increased expression of interstitial extra-
cellular matrix proteins10. wang et al. have presented 
a hypothesis that deficiency of BMP-7 signaling may 
play crucial role in podocyte damage in early diabetes 
in rodents, and its prevention has an important role 
in reducing diabetic renal injury. They suggest endog-
enous glomerular BMP-7 as an autocrine regulator of 
podocyte integrity in vivo11.
recent data collected on a diabetic mouse model 
of diabetic nephropathy which disregard the physio-
logical differences between the rat and mouse models, 
have reaffirmed the observation that the progression 
of diabetic nephropathy leads to decreased BMP-7 
expression. These data show that BMP-7 has a crucial 
role in adult kidney function, especially in the protec-
tion from renal injury in diabetic condition12. 
Studies on rodents have shown that BMP-7 is an 
effective therapy for diabetic nephropathy, especially 
in reversing proteinuria. diabetic injury resulted in 
the loss of tubular epithelial and glomerular podocyte 
phenotype manifested as the loss of BMP-7 expres-
sion, and therapy with BMP-7 restored the pheno-
type of the collecting duct manifested by restoration 
of BMP-7 expression13. 
in our study, we postulated that expression of 
BMP-7 is different among stages of diabetic nephrop-
athy on human kidney biopsies, and that it might be 
associated with the severity of disease. Therefore, the 
objective of this study was to analyze whether expres-
sion of BMP-7 is significantly changed in advanced 
stages of human diabetic nephropathy.
Materials and Methods
Human tissue
renal tissue samples for immunohistochemical 
analysis of the expression of BMP-7 were obtained 
from the archives of the department of Pathology and 
Cytology, Zagreb university hospital Center, Za-
greb, Croatia, from 30 patients with previously histo-
logically confirmed diagnosis of diabetic nephropathy. 
during the processing, two of the samples were ex-
tracted from the analysis due to material insufficiency. 
healthy kidney tissue of 12 human kidneys obtained 
after surgical nephrectomy in patients with localized 
renal tumors was used as controls. Mean age of the 
controls was 58.8±4.3 years and 67% were men.
For determination of the stage of diabetic neph-
ropathy we used the renal Pathology Society re-
search Committee classification, which divides 
diabetic nephropathy into four stages of glomerular 
lesions based on the degree of interstitial and vascular 
involvement14.
Immunohistochemistry
Anti-human BMP-7 monoclonal antibodies 
(r&d Systems, uSA) were used for immunohis-
tochemistry. Paraffin sections (4-5 μm) were deparaf-
finized, antigen BMP-7  masked in the Pt-module 
(dakoCytomation, denmark) at 97 °C for 20 min-
utes in a buffer from enVision Flex commercial kit 
(K8010, dakoCytomation, denmark) and processed 
by standard automated method in the Autostainer + 
camera (dakoCytomation, denmark), then stained 
with hematoxylin. 
Quantification
globally sclerosed glomeruli were excluded from 
analysis. results of immunohistochemistry were as-
sessed using a light microscope, on at least five fields 
under high magnification (x400). The presence of 
staining in >5% of cells was considered another posi-
tive expression of BMP-7. BMP-7 immunostaining 
was semiquantitatively evaluated for intensity as pre-
viously described15.
Statistical analysis was carried out using Statistica 
(version 10) and MedCalc 12.0 computer program.
Results
Patient characteristics
Three patients had diabetes type 1 and 25 patients 
diabetes type 2. At the time of biopsy, the youngest 
patient was aged 24 and the oldest 70, average age 53 
years. There were 60% of male patients. Biopsies were 
conducted in the period from 1998 through 2012. 
BMP-7 expression in proximal tubules
BMP-7 was differently expressed in the cytoplasm 
of epithelial cells of proximal tubules and podocytes at 
all stages of diabetic nephropathy (Fig. 1).
Four patients had diabetic nephropathy stage i or 
ii, and BMP-7 was in all cases strongly positive (3+) 
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in proximal tubules. twenty-four patients had stage 
iii or iV diabetic nephropathy, and BMP-7 expres-
sion was of medium intensity (2+) in 7 samples, while 
strong intensity (3+) was found in 17 samples (not sig-
nificant) (Fig. 2). 
BMP-7 expression in control samples was less in-
tensive than at the initial stages of diabetic nephropa-
thy (not significant).
BMP-7 expression in podocytes
expression of BMP-7 in podocytes was variable. 
BMP-7 expression at initial stages of diabetic neph-
ropathy was high, either 2+ or 3+. At advanced stages, 
low expression (1+) was recorded in the majority of 
samples. Thus, at stage iii, 1+ BMP-7 expression 
was found in 62.5%s, 2+ in 12.5% and 3+ in 25% of 
samples. At stage iV, 50% of samples had expression 
1+, 14% 2+, while the remaining 36% had high (3+) 
intensity of BMP-7 expression (Fig. 3).  
Discussion
Over the last decade, BMP-7 has emerged as an 
antifibrogenic agent. exogenously administered rh-
BMP-7 reduced renal fibrosis in experimental mod-
els of unilateral obstructive nephropathy or diabetic 
glomerular sclerosis16,17.  in the rat model of strepto-
zotocin-induced diabetic nephropathy, BMP-7 was 
found to partially reverse diabetes-induced kidney 
hypertrophy, restore glomerular filtration rate, urine 
albumin excretion, and glomerular histology13. 
BMP-7 exerts antifibrogenic actions in vitro by 
inducing Smad signals that block activation and nu-
clear translocation of tgF-β-induced Smad 2/318. in 
cultured cells, BMP-7 acts as a counter-regulator of 
tgF-β profibrogenic actions19. BMP-7 decrease oc-
curred early in kidneys of experimental animals, even 
before the progression of structural damage to the 
kidneys10. 
in this study, we examined the expression of 
BMP-7 at different stages of diabetic nephropathy in 
humans. Our results revealed that BMP-7 expression 
increased at the initial stages of diabetic nephropathy, 
with subsequent decrease at advanced stages of the 
disease. it is probably a protective mechanism that oc-
curs in order to protect kidney structure or function. 
however, it is in contrast with the loss of endogenous 
Fig. 1. BMP-7 is highly positive in the cytoplasm of epi-
thelial tubular cortex and in podocytes (X400).
Fig. 2. Expression of BMP-7 in proximal tubules at dif-
ferent stages of diabetic nephropathy.
BMP 7 in the proximal tubule
Fig. 3. Expression of BMP-7 in podocytes at different 
stages of diabetic nephropathy.
BMP in podocytes
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renal BMP-7 that has been observed in early diabe-
tes in rodents10. BMP-7 expression in proximal tubu-
lar cells was strongly positive at early stages and less 
intensive at advanced stages. expression of BMP-7 
in podocytes was less consistent. At initial stages of 
diabetic nephropathy it was high, 2+ or 3+, while at 
advanced stages, the majority of samples exerted low 
expression (1+). Also, marked expression of BMP-7 
at initial stages of diabetic nephropathy compared to 
control group was found. 
BMP-7 was proposed as a survival factor for pod-
ocytes in animal models of diabetic nephropathy11, 
as it was found for neuronal cells20. Maintenance of 
BMP-7 in podocytes improves podocyte survival, 
which may account for lesser albuminuria in dia-
betic mice that express the BMP-7 transgene com-
pared with their wt counterparts. it was not found 
to affect the diabetes-induced increase in tgF-β 
but reduces early accumulation of collagens and fi-
bronectin and maintains renal collagenase activity, 
consistent with the tgF-β activity-opposing action. 
The beneficial effect of BMP-7 on podocyte survival 
may also be explained by its antagonism to the ef-
fects of tgF-β21.
Although samples of patients with more advanced 
stages of diabetic nephropathy had a decreased inten-
sity of BMP-7 staining compared to samples obtained 
at initial stages of the disease, the difference was not 
statistically significant. 
The major limitation of our study was a small 
sample size. Further investigations with large samples 
are needed to determine the significance of such find-
ings with certainty. however, data on human samples 
are valuable as they partially support data from ani-
mal experiments that emphasize the role of BMP-7 
in preservation of kidney structure and function. 
higher-than-normal expression of BMP-7 at initial 
stages of diabetic nephropathy may be in line with 
these findings. in human diabetic nephropathy, turk 
et al. showed that the loss of podocytes and podocyte 
differentiation markers is associated with a decreased 
BMP signaling activity9. Our findings of increased 
BMP-7 expression in early diabetic nephropathy 
samples could indicate a disorder in BMP receptors or 
the cell signaling pathway that results in consecutive 
overstimulation of BMP-7, so future research should 
be focused in this direction.  
Conclusion
increased expression of BMP-7 at initial stages 
of diabetic nephropathy with subsequent decrease at 
advanced stage highlights the role of BMP-7 in the 
protection of kidney structure and function. Further 
investigations should be focused on disturbances of 
BMP-7 receptors and signaling pathways in patients 
with diabetic nephropathy.
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Sažetak
iZrAžAJ KOŠtAnOg MOrFOgenetSKOg PrOteinA-7 Je Snižen u huMAnOJ diJABetiČKOJ 
neFrOPAtiJi
R. Ivanac-Janković, M. Ćorić, V. Furić-Čunko, V. Lovčić, N. Bašić-Jukić i P. Kes
Koštani morfogenetski protein-7 (engl. bone morphogenetic protein-7, BMP-7) izražen je u svim dijelovima bubrežnog 
parenhima zdravih bubrega, najviše u epitelnim stanicama proksimalnih kanalića. glavna mu je uloga zaštita bubrega od 
akutne i kronične ozljede, upale i razvoja fibroze. dijabetička nefropatija je vodeći uzrok kroničnog zatajenja bubrega, a 
obilježena je smanjenim izražajem BMP-7. Cilj našega rada bio je istražiti mijenja li se izražaj BMP-7 s napredovanjem 
humane dijabetičke nefropatije ovisno o stadijima bolesti. imunohistokemijskom metodom analizirali su se arhivski uzorci 
materijala 30 bolesnika kojima je učinjena biopsija bubrega te potvrđena dijagnoza dijabetičke nefropatije. rezultati su 
pokazali da je BMP-7 različito izražen u citoplazmi epitelnih stanica proksimalnih kanalića i podocita između pojedinih 
stadija dijabetičke nefropatije. u ranijim stadijima, u proksimalnim kanalićima i podocitima uočen je snažno pozitivan 
izražaj, dok je slab izražaj zabilježen u većini uzoraka kasnijih stadija bolesti. u zaključku, povećan izražaj BMP-7 u po-
četnim stadijima dijabetičke nefropatije s kasnijim smanjenjem izražaja u poodmaklim stadijima naglašava ulogu BMP-7 
u zaštiti strukture i funkcije bubrega. daljnja istraživanja u bolesnika s dijabetičkom nefropatijom potrebno je usmjeriti na 
otkrivanje poremećaja na razini BMP-7 receptora i signalnih putova.
Ključne riječi: Bubreg; Koštani morfogenetski protein-7; Dijabetička nefropatija; Bubrežni kanalići, proksimalni; Podociti; 
Imunohistokemija 
